Targanta Therapeutics Corp.

Targanta Therapeutics Corporation (Targanta) is a bio-pharmaceutical company that is focused on developing and commercializing innovative antibiotics used in the treatment of serious infections in the hospital and other institutional settings. Its pipeline includes an intravenous version of oritavancin, which is a semi-synthetic lipoglycopeptide antibiotic, and a program to develop an oral version of oritavancin for the possible treatment of Clostidium difficile-related infection. The company also has other pipeline products in antibacterial agents, in pre-clinical development that target Clostridium difficile-related conditions. As of 26 February 2009, Targanta has been acquired by The Medicines Company and is headquartered in Cambridge, Massachusetts, the US.

Street: 
222 Third Street
City: 
Cambridge
Postcode: 
02142
Federal State : 
United States
WebSite: 
www.targanta.com
Fax: 
1-617-5779021

Company Index Score

Current Index Score Historical Index Score
  • Targanta Therapeutics Corp. currently scores 50 % in the index.
  • Targanta Therapeutics Corp. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Targanta Therapeutics Corp. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets